New hope for recurrent ovarian cancer? early trial combines novel PARP inhibitor with chemo

NCT ID NCT06930755

Recruiting now Disease control Sponsor: Nerviano Medical Sciences Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-stage study tests a new experimental drug (NMS-03305293) combined with a standard chemotherapy (topotecan) in about 24 people whose ovarian cancer has returned after previous treatments. The main goals are to check safety and find the best dose, while also seeing if the combination shrinks tumors. It is for patients who have tried up to 5 prior therapies and have no other standard options left.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for FALLOPIAN TUBE CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

fallopian tube cancer ovarian cancer ovarian serous adenocarcinoma peritoneum cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

OVARIAN CANCER

Contacts and locations

Show contact details

Study contacts

Contact

Email: •••••@•••••

Locations

OSF Saint Francis Medical Center
RECRUITING

Peoria, Illinois, 61637, United States
Penn Medicine - Perelman Center for Advanced Medicine
RECRUITING

Philadelphia, Pennsylvania, 19104, United States
Tennessee Oncology
RECRUITING

Nashville, Tennessee, 37203, United States
The University of Texas MD Anderson Cancer Center
RECRUITING

Houston, Texas, 77030, United States
Washington University School of Medicine in St. Louis
RECRUITING

St Louis, Missouri, 63130, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.